

VU Research Portal

Increased mortality in depressive disorders: A review.

Cuijpers, W.J.M.J.; Schoevers, R.A.

published in

Current Psychiatry Reports
2004

DOI (link to publisher)

[10.1007/s11920-004-0007-y](https://doi.org/10.1007/s11920-004-0007-y)

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Cuijpers, W. J. M. J., & Schoevers, R. A. (2004). Increased mortality in depressive disorders: A review. *Current Psychiatry Reports*, 6, 430-437. <https://doi.org/10.1007/s11920-004-0007-y>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Increased Mortality in Depressive Disorders: A Review

Pim Cuijpers, PhD* and Robert A. Schoevers, MD

Address

*Department of Clinical Psychology, Vrije Universiteit, Amsterdam, Van der Boechorststraat 1, 1081 BT Amsterdam, The Netherlands. E-mail: P.Cuijpers@psy.vu.nl

Current Psychiatry Reports 2004, 6:430–437

Current Science Inc. ISSN 1523-3812

Copyright © 2004 by Current Science Inc.

Several factors have been proposed to explain the relationship between excess mortality and depressive disorders. These include mechanisms such as increased suicide rates, hazardous health behavior (smoking, alcohol use, unhealthy eating), psychologic reactions to developing a medical illness, biological dysregulations (hyperactivity of the hypothalamic pituitary adrenal, neuro-immune dysregulation, sympathoadrenergic dysregulation), and noncompliance with medical treatment. The evidence supporting the role of each of these mechanisms in excess mortality varies considerably. The causal direction in most of the mechanisms is not clear. It is possible that the explanatory factors, such as smoking, compliance, or biological mechanisms, cause depression, or that depression causes these factors, or that both are explained by a third, underlying factor. We will summarize the evidence supporting these mechanisms, and propose options for possible interventions aimed at reducing the increased risk of dying.

Introduction

The relationship between mental disorder and mortality has been examined in hundreds of studies worldwide in the past few decades, although some of the studies go back at least 150 years [1,2]. One of the mental disorders that has been examined in great depth is depression [3•]. Most of the studies exploring the relationship between depression and mortality have focused on whether mortality rates in people with a mental disorder are higher than in other populations. Relatively few studies have examined the processes through which mental disorders influence mortality risks. This research has resulted in an accumulation of evidence showing that subjects with depression have increased mortality rates. Several hypotheses have been developed to explain this phenomenon. However, the evidence supporting these hypotheses differs greatly for each one.

In this article, we first will summarize the results of epidemiologic research examining the relationship between

depression and mortality. We then will describe the hypotheses that have been posed to explain increased mortality in depression and the research supporting these hypotheses.

Are Mortality Rates Increased in Subjects with Depression?

The question of whether depression increases mortality rates has been examined in community studies [4•], in studies comparing patients treated for depression in the general population [3•], and in studies of medical patients, including depressed patients with heart diseases [5–8], patients who have had stroke [9], patients with a life-threatening illness [10], and elderly patients with varying illnesses [11–13].

Recently, we did a meta-analysis of prospective studies examining mortality rates in subjects with depression compared to the rest of the population [4•]. A systematic search of the literature in the most important bibliographic databases resulted in 25 prospective studies, reporting on a random sample from a community and comparing mortality rates in depressed to nondepressed subjects. These studies included 106,628 subjects, of whom 6416 were depressed. The overall relative risk (RR) of dying in depressed subjects was found to be 1.81 (95% CI, 1.58–2.07) compared with nondepressed subjects. Because the set of studies was significantly heterogeneous, we excluded the studies that contributed most to the heterogeneity until a homogeneous set of studies was obtained. The relative risk of the resulting set of studies (three studies were excluded) was found to be 1.65 (95% CI, 1.51–1.81).

In our meta-analysis, we included studies examining subjects with major depressive disorder according to diagnostic criteria and studies of subjects with subthreshold forms of depression. Subthreshold depression could be operationalized by scoring above a cut-off point on a self-rated depression questionnaire, by having one or more basic characteristics of depression (mood problems for 2 weeks), or by meeting criteria for minor depression as operationalized in the Diagnostic and Statistical Manual IV, the International Classification of Diseases, 10th Revision, or the Research Diagnostic Criteria. We did not find any indication that the relative risk in subjects with major depression (1.54; 95% CI, 0.96, 2.47) was higher than in subjects with subthreshold forms of depression (1.65; 95% CI, 1.39, 1.96). These results are supported by several other

Table 1. Possible causes of increased mortality in depression

Increased suicide rates in depressed patients
More hazardous health behaviors in depressed patients
Tobacco use
Unhealthy eating habits
Alcohol use
Less physical activity
Hazardous behavior such as dangerous driving
Depression is a psychologic reaction to medical illnesses*
Biological dysregulations
Hyperactivity of the hypothalamic pituitary adrenal
Neuro-immune dysregulation
Sympatho-adrenergic dysregulation
"Vascular" depression (in the elderly)
Less compliance with treatment in depressed patients

*Excess mortality is not caused by depression, but by the illness.

systematic reviews and meta-analyses of studies examining mortality and depression [3•,14,15••,16].

In some community studies, subjects with major depression and subjects with subthreshold depression were examined [17•,18,19], and direct comparisons between these two populations within each of these studies confirm that there is no strong evidence of a significant difference in mortality rates.

Some studies found indications that the increased risk of death especially is present in men, but is not present or is less so in women [17•,19–21]. In our meta-analysis, we also found support for this difference between men and women. The relative risk of dying was 2.25 (95% CI, 1.90, 2.67) in men, compared to 1.62 (95% CI, 1.37, 1.92) in women. In a multivariate metaregression analysis in which we controlled for several possible confounding variables, the difference between men and women remained considerable.

Depressive disorder is not the only mental disorder with increased mortality rates. In a large systematic review of more than 150 studies, evidence showed that mortality rates are increased in all mental disorders, including eating disorders, alcohol and drug dependence and abuse, schizophrenia, bipolar disorders, dysthymia, anxiety disorders, personality disorders, and major depressive disorders [3•]. It also was found in this review that the highest risks for premature deaths were found in substance abuse and eating disorders. However, the risk of death from unnatural causes is especially high in functional disorders, particularly in schizophrenia and major depression.

Possible Causes of Increased Mortality Rates in Depression

On the basis of our meta-analysis, we can calculate the population-attributable risk of depression. This indicates the percentage of deaths that can be avoided if the risk factor (in this case depression) were to be erased altogether.

We found the population-attributable risk to be 7.5 %. This is considerable when compared to lifestyle factors [22]. Among these lifestyle factors only tobacco use (18.1%) and poor diet and lack of physical exercise (16.6%) result in more deaths than depressive disorders. Other major lifestyle factors, such as alcohol consumption (3.5%), score considerably lower than depressive disorder.

However, depression cannot be directly compared to these lifestyle factors, as there is much more evidence supporting the causal link between lifestyle factors and increased mortality. A direct causal relation between depression and mortality has not been proven, and it is possible that the increased mortality is not directly caused by depression. We will describe the most important causes of increased mortality in depression that have been proposed, and the supporting evidence. The most important mechanisms explaining the relationship between excess mortality and depression are summarized in Table 1.

Suicide

There are several behavioral causes of the increased mortality in depression and suicide is among the most important. Suicide rates in depressive disorders have been studied for several decades [23]. Although the risk of suicide has long been overestimated in depression, a recent meta-analysis of 47 studies estimated that the lifetime risk of suicide ranges from 2.2% to 8.6% in patients with depression [24], compared with less than 0.5% in nondepressed subjects. The lifetime prevalence was found to be especially large in patients hospitalized for suicidality (8.6%). The lifetime prevalence found in mixed inpatient/outpatients with depression has been found to be 2.2%.

Although suicide is one of the causes of increased mortality in depression, it can explain only a small part of the overall increased mortality because the incidence of suicide is low. Most studies examining the correlation between mortality and depression do not examine differences in actual causes of death between depressed and nondepressed subjects, and most do not have sufficient statistical power to examine these differences. However, there are some exceptions. In a well-designed longitudinal study of elderly people living in the community in the Netherlands, in which 124 subjects with minor or major depression died during 50 months follow-up, only one died because of suicide [17•]. And in a large survey in the United States among almost 46,000 households, it was found that among 223 depressed subjects who died, only two died because of suicide [20].

These figures must be interpreted with caution, because it is known that many suicides are not registered as such in the official statistics. Nonetheless, suicide can never explain more than only a small part of the increased mortality rates in depressed patients.

Tobacco Use

Another mechanism that is assumed to be responsible for increased mortality in depression is hazardous health behavior. It has been established that patients with depression smoke more, stop smoking less easily, have more unhealthy eating habits, drink more alcohol, have less physical activity, and engage in more hazardous behavior, such as dangerous driving.

It has been known for several decades that smokers are more neurotic than nonsmokers [25–27]. These early studies also showed that smokers who ceased smoking were less neurotic, less depressed, and less anxious than those who did not succeed in their attempt to quit. Several more recent studies have shown that there also is a relationship between smoking and depressive disorders that meet rigorous criteria. Compared with nonsmokers, smokers often have had a depressive disorder in their lives [28–30]. This relationship between depressive disorders and smoking has been shown to exist as early as in adolescence [31]. There also is evidence that the likelihood of entering a new episode of major depression is greater among smokers than among nonsmokers [30,32]. Additionally, research has shown smokers with a history of major depression fail their attempts at smoking cessation more often than other smokers [28,30]. When smokers with a history of depression stop, they have a significantly increased risk of developing a new depressive disorder as compared with smokers without a history of depression [32].

Although the evidence clearly points to a strong relationship between tobacco use and depression, there is little evidence about the exact nature of this relationship and causal directions. It has been suggested that depression may be caused by smoking through neurochemical changes [33••], that depression leads to smoking by increasing the likelihood that individuals will self-medicate negative feelings with nicotine [27], and that depression and smoking are caused by common physical or psychologic factors that independently increase the risk of both conditions [33••].

Other Hazardous Health Behaviors

Tobacco use is only one of the unhealthy lifestyle factors that are more prevalent in patients with depressive disorder than in other subjects. It has been shown repeatedly that patients with depression more often drink too much alcohol [34–37], although there are indications that this is not true in elderly subjects [17•,38]. There also is some evidence that problem drinking has a negative effect on prognosis of depressive disorder.

Several other studies found that depressive disorder is associated with body mass index [39,40] and obesity [41], especially among subjects with severe obesity. Depressive disorders also have been found to be associated with lower physical activity [17•], and with a larger number of fatal accidents [42].

The relationship between these lifestyle factors and depression also can work in the three directions cited earlier: lifestyle factors may cause depression, depression may cause differences in lifestyle, or both may be the result of one or more independent factors.

Mortality in Depressed Patients With General Medical Illnesses

As indicated previously, depression has been shown to be more prevalent in several general medical illnesses, including diabetes [43], heart diseases [5–8], cancer [44,45], stroke [9], arthritis, osteoporosis, Alzheimer's disease [46•], and life-threatening illness in general [10]. It has been concluded that the prevalence rates of depression increase from 2% to 5% in community settings, to 5% to 10% in primary care, and to 6% to 14% or greater in medical and/or surgical patients [47–49].

It has been suggested that some patients develop depressive symptoms as a psychologic reaction to these illnesses, and that the increased risk of mortality is not caused by depression, but because of the illnesses that also cause the depressive symptoms [50]. In these cases, getting an illness is considered to be an important life event. These psychologic reactions to illnesses cannot explain all increased mortality. It also has been shown that subjects with depression also have an increased risk of developing new general medical illnesses, and this has been shown especially for cardiovascular disease [51–53] and diabetes [54,55].

Additionally, there is evidence that the prognosis of patients with depression is in many cases worse than the prognosis of patients without depression, such as in patients with myocardial infarction [6]. However, this could be explained by the phenomenon that illnesses with a poor prognosis are more depressing than less serious conditions [56••].

Depression and Biological Dysregulations

Another possible explanation for the association between depression and excess mortality is biological, occurring through neuroendocrine and autonomic dysregulation.

Hyperactivity of the hypothalamic pituitary adrenal (HPA) axis frequently has been established in patients with depression [57,58]. Through insufficient negative feedback of the glucocorticoid receptors in the hippocampus and the hypothalamic paraventricular nucleus [58], excess production of hypothalamic CRH leads to higher hypophyseal adrenocorticotrophic hormone release, which in turn causes higher blood cortisol levels [59]. Hypercortisolemia is associated with insulin resistance and accumulation of intra-abdominal fat [60]. The combination of “upper-body obesity,” diabetes, hypertension and dyslipidemia, also called “deadly quartet,” is associated with a significantly higher risk of myocardial infarction and stroke [61]. Through lower bone density, hypercortisolemia also is associated with an increased likelihood of

bone fracture [62]. There has been debate on whether these PHA axis abnormalities precede affective disorder, or result from chronic stress, traumatization, and depression. Genetic studies have shown that polymorphisms in the glucocorticoid receptors are associated with the occurrence of affective disorders, [58,63,64] and healthy family members of patients with depression have been shown to have HPA axis overactivity [64]. Therefore, HPA axis abnormalities may participate in the development of depressive symptoms and in the occurrence of numerous medical conditions.

A second pathogenetic mechanism, possibly explaining the association between depression and excess mortality, is neuro-immune dysregulation. Patients with depression show higher levels of pro-inflammatory cytokines such as interleukins (IL) IL-1 and IL-6, C-reactive protein, and α -1 antichymotrypsin [65,66]. These are associated with hypercortisolemia, [67] myocardial infarction, and stroke [68–71]. The temporal associations between depression and neuro-immune dysregulation still must be elucidated because low doses of endotoxins have been shown to cause symptoms of depression, anxiety, and cognitive disturbances in healthy volunteers [72,73].

A third mechanism is sympathoadrenergic dysregulation. Depression is associated with increased noradrenaline levels [68], and autonomic hyperactivity leading to reduced heart rate variability and an increase in coronary events [74,75•]. Through autonomic dysregulation, upregulation of platelet serotonin receptors and increased intracellular calcium mobilization, platelet aggregation and thrombo-embolic processes also are enhanced [75•].

In the elderly, a specific subtype of vascular depression is distinguished with psychomotor retardation, loss of interest, a decrease in functional abilities, and vegetative symptoms. Patients are found to have cerebral (frontostriatal) white matter lesions most likely related to microvascular pathology, which also may affect longevity [76,77].

All of these biological mechanisms are linked to depression and are associated with various somatic disorders. However, the direction of these mechanisms is unclear. Again, it may be possible that these mechanisms cause the depression directly, that depression causes these mechanisms, or that the depression and the mechanisms are caused by a third factor.

Compliance with Medical Treatment

Another possible explanation for the increased mortality in depressed patients with general medical disorders is that compliance with treatment is less optimal than in other patients. There is ample support for this hypothesis in various patient groups such as patients with HIV [78], patients with cancer [79], and elderly patients with coronary artery disease [80]. A recent meta-analysis of the literature concluded that, compared with nondepressed patients, the odds are three times greater that patients with depression will be noncompliant with medical treatment recommendations [81].

Why depression affects adherence is unclear. It has been suggested that reduced adherence is related to other factors, such as poor social support, increased functional impairment, heightened sensitivity to physical discomforts, and impaired attention span, concentration, and memory. Each of these factors has been shown to be related to depression and to reduced compliance [80]. However, the most obvious explanation is that the depression reduces the motivation to adhere to a medical treatment.

It also has been suggested that it is not depression that causes poor adherence, but the behavior of noncompliance preceding the mood state [82]. More research is needed to clarify the causal link between depression and compliance.

Does Treatment of Depression Affect Survival?

In the preceding paragraphs, we have described the mechanisms that may explain excess mortality rates in depression. Because there are several mechanisms that may be interlinked, excess mortality probably is caused by several different pathways. Theoretically, there are several different methods to intervene in these pathways. Although it is beyond the scope of this article to describe them all, we will describe some major possible interventions.

First, as most suicides are committed by subjects with depression, effective suicide prevention programs may reduce mortality rates in depressed subjects. Generally, there is little evidence that suicide prevention programs are effective, mostly because of a lack of randomized controlled trials and small sample sizes [83]. However, there are some promising interventions, such as long-term lithium treatment [84], and some recent studies show promising effects of psychosocial interventions [85–87].

Another possibility is to improve lifestyle factors in patients with depression. Most research in this area has focused on tobacco use. Several trials have examined the effects of cognitive behavior therapy in smokers with a lifetime history of major depression [88–91]. Most of these studies show positive results, although most of the sample sizes are small and more research in this area is needed. Comparable approaches could be possible, focusing on other lifestyle factors.

A recent meta-analysis of studies examining the effects of interventions aimed at the improvement of medication adherence showed that this type of intervention has small to moderate effects [92]. However, only one of the studies examined by this meta-analysis was aimed at subjects with depression, and the effect size for this study was small.

Another important research question is whether adequate treatment of depression may affect the risk of mortality. Theoretically, treatment with antidepressant medication could result in better survival and excess mortality. Tricyclic antidepressants may cause ventricular arrhythmias and orthostatic hypotension. In medical (cardio) and elderly patients these side effects may have substantial negative consequences [93,94]. However, it is

unlikely that this could be responsible for the excess mortality in depression. Sparsely available earlier studies suggest that adequate treatment of depression may reduce mortality [95,96]. Antidepressants have been shown to affect event-free interval in patients who have had MI [97]. One placebo-controlled trial found that 9-year survival after stroke was significantly better if patients had been given antidepressants for some time soon after their stroke, regardless of the presence or absence of depression [98]. Research has shown that antidepressant medication may directly affect numerous biological parameters. Selective serotonin re-uptake inhibitors have been shown to normalize platelet aggregation, and may influence cardiovascular risk patterns [99]. Recent research indicates that antidepressants may help to restore normal functioning of the HPA axis in individuals with depression [100,101]. However, possible effects on survival have not been shown consistently. Recently, this idea was investigated more thoroughly in two large randomized placebo-controlled trials. One study of 369 cardiac patients found that sertraline could safely and effectively be used to treat depression in patients with acute MI or unstable angina, although it did not show an improvement in cardiologic parameters [102]. Another study specifically investigated the impact of treatment on 6-months survival in 2481 patients after MI and found that cognitive behavior therapy, with the addition of SSRI improved severe depression and social isolation, but not event-free interval [103].

Psychotherapy or psychosocial interventions aimed at reducing depression also may influence survival. A meta-analysis of psychosocial interventions showed that the addition of psychosocial treatments to standard cardiac rehabilitation regimens reduced mortality and morbidity, psychologic distress, and some biological risk factors during the first 2 years [104]. Providing psychosocial support reduces depression, anxiety, and pain in patients with cancer, but studies are divided on whether this also increases survival time [44].

Overall, it can be concluded that interventions aimed at either of the pathways linking depression and excess mortality have beneficial effects on a number of clinically relevant biological and psychologic parameters, but currently it is not an established fact that survival of patients with depression can be improved substantially by these measures.

Conclusions

There is little doubt that there is a relationship between depression and excess mortality. However, the mechanisms explaining this relationship are less clear. Several behavioral and physical mechanisms have been proposed. The evidence supporting the role of each of these mechanisms in excess mortality varies greatly. The causal direction in most of the mechanisms is not clear. It is possible that the explanatory factors, such as smoking, compliance, or neurobiological dysregulation cause depression. It also is pos-

sible that depression causes these factors, or that both are explained by a third, underlying factor.

The mechanisms explaining excess mortality in depression may be interlinked with each other in complex ways. For example, lifestyle factors may trigger biological vulnerability and psychologic reactions to getting an illness and may increase suicide risk. It also is possible that underlying pathogenetic mechanisms and genetic polymorphisms may constitute higher vulnerability for depression and medical illnesses.

This suggests that excess mortality is a result of complex interactions between different factors, and depression may lead to mortality through different pathways.

We must conclude that the relationship between depression and excess mortality is not yet well understood, and although several possible mechanisms explaining this relationship are suggested, more research is needed before interventions will become available to reduce this increased risk of death in patients with depression.

Acknowledgements

Dr. Schoevers is affiliated with Metrum Mental Health Care Amsterdam and the Department of Psychiatry, VU Medical Centre, Amsterdam, The Netherlands.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Brown S: **Excess mortality in schizophrenia; a meta-analysis.** *Br J Psychiatry* 1997, **171**:502–508.
2. Pokorski RJ: **Underwriting psychiatric impairments, with emphasis on depression; part I: psychiatric mortality and common underwriting parameters.** *J Insurance Med* 1994, **26**:46–56.
3. Harris EC, Barraclough B: **Excess mortality of mental disorder.** *Br J Psychiat* 1998, **173**:11–53.

This is a systematic review of studies examining the relationship between excess mortality and most mental disorders, including major depression and other mood disorders.

4. Cuijpers P, Smit F: **Excess mortality in depression: a meta-analysis of community studies.** *J Affect Disord* 2002, **72**:227–236.

This is a quantitative meta-analysis of prospective community studies examining the mortality of subjects with depression.

5. Januzzi Jr JL, Stern TA, Pasternak RC, DeSanctis RW: **The influence of anxiety and depression on outcomes of patients with coronary artery disease.** *Arch Intern Med* 2000, **160**:1913–1921.
6. Frasure-Smith N, Lesperance F, Talajic M: **Depression following myocardial infarction. Impact on 6-month survival.** *JAMA* 1993, **270**:1819–1825.
7. Frasure-Smith N, Lesperance F, Talajic M: **Depression and 18-month prognosis after myocardial infarction.** *Circulation* 1995, **15**:999–1005.
8. Aromaa A, Raitasalo R, Reunanen A, et al.: **1994. Depression and cardiovascular diseases.** *Acta Psychiatr Scand* 1994, **377**(suppl):77–82.
9. Morris PL, Robinson RG, Andrzejewski P, et al.: **Association of depression with 10-year poststroke mortality.** *Am J Psychiatry* 1993, **150**:124–129.

10. Silverstone PH: **Depression increases mortality and morbidity in acute life-threatening medical illness.** *J Psychosom Res* 1990, **34**:651–657.
11. Koenig HG, George LK, Larson DB, et al.: **Depressive symptoms and nine-year survival of 1,001 male veterans hospitalized with medical illness.** *Am J Geriatr Psychiatry* 1999, **7**:124–131.
12. Covinsky KE, Kahana E, Chin MH, et al.: **Depressive symptoms and 3-year mortality in older hospitalized medical patients.** *Ann Intern Med* 1999, **130**:563–569.
13. Ganzini L, Smith DM, Fenn DS, Lee LA: **Depression and mortality in medically ill older adults.** *J Am Geriatr Soc* 1997, **45**:307–312.
14. Wulsin LR, Vaillant GE, Wells VE: **A systematic review of the mortality of depression.** *Psychosom Med* 1999, **61**:6–17.
15. Saz P, Dewey ME: **Depression, depressive symptoms and mortality in persons aged 65 and over living in the community: a systematic review of the literature.** *Int J Geriatr Psychiatry* 2001, **16**:622–630.

This is a comprehensive and well-conducted systematic review of studies examining the relationship between depression and mortality in the elderly.

16. Cole MG, Bellavance F: **Depression in elderly medical inpatients: a meta-analysis of outcomes.** *CMAJ* 1997, **157**:1055–1060.
17. Penninx BW, Geerlings SW, Deeg DJ, et al.: **Minor and major depression and the risk of death in older persons.** *Arch Gen Psychiatry* 1999, **56**:889–895.

This is one of the most important studies in this area, examining the relationship between depression and mortality, while controlling for the most important confounders

18. Sharma VK, Copeland JR, Dewey ME, et al.: **Outcome of the depressed elderly living in the community in Liverpool: a 5-year follow-up.** *Psychol Med* 1998, **28**:1329–1337.
19. Schoevers RA, Geerlings MI, Beekman AT, et al.: **Association of depression and gender with mortality in old age. Results from the Amsterdam Study of the Elderly (AMSTEL).** *Br J Psychiatry* 2000, **177**:336–342.
20. Zheng D, Macera CA, Croft JB, et al.: **Major depression and all-cause mortality among white adults in the United States.** *Ann Epidemiology* 1997, **7**:213–218.
21. Murphy JM, Monson RR, Olivier DC, et al.: **Affective disorders and mortality. A general population study.** *Arch Gen Psychiatry* 1987, **44**:473–480.
22. Mokdad AH, Marks JS, Stroup DF, Gerberding JL: **Actual causes of death in the United States.** *JAMA* 2004, **291**:1238–1245.
23. Guze SB, Robins E: **Suicide and primary affective disorders.** *Br J Psychiatry* 1970, **117**:437–438.
24. Bostwick JM, Pankratz VS: **Affective disorders and suicide risk: A reexamination.** *Am J Psychiatry* 2000, **157**:1925–1932.
25. Eysenck HJ: **Personality and the maintenance of the smoking habit.** In *Smoking Behavior: Motives and Incentives*. Edited by Dunn WL. Washington, DC: Winston; 1973.
26. Pomerleau O, Adkins D, Pertschuk M: **Predictors of outcome and recidivism in smoking cessation treatment.** *Addict Behav* 1979, **3**:65–370.
27. Hall SM, Muñoz RF, Reus VI, Sees KL: **Nicotine, negative affect, and depression.** *J Consult Clin Psychol* 1993, **61**:761–767.
28. Glassman AH, Helzer JE, Covey LS, et al.: **Smoking, smoking cessation, and major depression.** *JAMA* 1990, **264**:1546–1549.
29. Anda RF, Williamson DF, Escobedo LG, et al.: **Depression and the dynamics of smoking: a national perspective.** *JAMA* 1990, **264**:1541–1545.
30. Breslau N, Kilbey MM, Andreski P: **Nicotine dependence and major depression; new evidence from a prospective investigation.** *Arch Gen Psychiatry* 1993, **50**:31–35.
31. Brown RA, Lewinsohn PM, Seeley JR, Wagner EF: **Cigarette smoking, major depression, and other psychiatric disorders among adolescents.** *J Am Child Adolesc Psychiatry* 1996, **35**:1602–1610.
32. Covey LS, Glassman AH, Stetner F: **Major depression following smoking cessation.** *Am J Psychiatry* 1997, **154**:263–265.

33. Dierker LC, Avenevoli S, Stolar M, Merikangas KR: **Smoking and depression: An examination of mechanisms of comorbidity.** *Am J Psychiatry* 2002, **159**:947–953.

This is an excellent review of studies examining the relationship between depression and smoking.

34. Holahan CJ, Moos RH, Holahan CK, et al.: **Drinking to cope and alcohol use and abuse in unipolar depression: a 10-year model.** *J Abnorm Psychol* 2003, **112**:159–165.
 35. Roeloffs CA, Fink A, Unutzer J, et al.: **Problematic substance use, depressive symptoms, and gender in primary care.** *Psychiatr Serv* 2001, **52**:1251–1253.
 36. Aneshensel CS, Huba GJ: **Depression, alcohol use, and smoking over one year: a four-wave longitudinal causal model.** *J Abnorm Psychol* 1983, **92**:134–150.
 37. Stephens T: **Physical Activity and Mental Health in the United States and Canada: Evidence From Four Population Surveys.** *Prev Med* 1988, **17**:35–47.
 38. Rodgers B, Korten AE, Jorm AF, et al.: **Non-linear relationships in associations of depression and anxiety with alcohol use.** *Psychol Med* 2000, **30**:421–432.
 39. Carpenter KM, Hasin DS, Allison DB, Faith MS: **Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: results from a general population study.** *Am J Public Health* 2000, **90**:251–257.
 40. Blazer DG, Hybels CF, Pieper CF: **The Association of depression and mortality in elderly persons: a case for multiple, independent pathways.** *J Gerontol Med Sci* 2001, **56A**:M505–M509.
 41. Onyike CU, Crum RM, Lee HB, et al.: **Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey.** *Am J Epidemiol* 2003, **158**:1139–1147.
 42. Pokorski RJ: **Underwriting psychiatric impairments, with emphasis on depression; part I: psychiatric mortality and common underwriting parameters.** *J Insurance Med* 1994, **26**:46–56.
 43. Lustman PJ, Anderson RJ, Freedland KE, et al.: **Depression and poor glycemic control: a meta-analytic review of the literature.** *Diabetes Care* 2000, **23**:934–942.
 44. Spiegel D, Giese-Davis J: **Depression and cancer: mechanisms and disease progression.** *Biol Psychiatry* 2003, **54**:269–282.
 45. Pirl WF, Roth AJ: **Diagnosis and treatment of depression in cancer patients.** *Oncology (Huntingt)* 1999, **13**:1293–1301.
 46. Kiecolt-Glaser J, Glaser R: **Depression and immune function; Central pathways to morbidity and mortality.** *J Psychosom Res* 2002, **53**:873–876.
- This is an excellent overview of the relationship between depression and immune function
47. Katon W, Ciechanowski P: **Impact of major depression on chronic medical illness.** *J Psychosom Res* 2002, **53**:859–863.
 48. Wells KB, Rogers W, Burnam A, et al.: **How the medical comorbidity of depressed patients differs across health care settings: results from the medical outcomes study.** *Am J Psychiatry* 1991, **148**:1688–1696.
 49. Katon W, Sullivan MD: **Depression and chronic medical illness.** *J Clin Psychiatry* 1990, **51**(suppl):3–11.
 50. Roose SP, Glassman AH, Seidman SN: **Relationship between depression and other medical illnesses.** *JAMA* 2001, **286**:1687–1690.
 51. Joynt KE, Whellan DJ, O'Conner CM: **Depression and cardiovascular disease: mechanisms of interaction.** *Biol Psychiatry* 2003, **54**:248–261.
 52. Penninx BW, Beekman AT, Honig A, et al.: **Depression and cardiac mortality: results from a community-based longitudinal study.** *Arch Gen Psychiatry* 2001, **58**:221–227.
 53. Ford DE, Mead LA, Chang P, et al.: **Depression is a risk factor for coronary artery disease in men: the precursors study.** *Arch Intern Med* 1998, **158**:1422–1426.
 54. Eaton WW, Armenian H, Gallo J, et al.: **Depression and risk for onset of type II diabetes. A prospective population-based study.** *Diabetes Care* 1996, **19**:1097–1102.

55. Kawakami N, Takatsuka N, Shimizu H, Ishibashi H: **Depressive symptoms and occurrence of type 2 diabetes among Japanese men.** *Diabetes Care* 1999, **22**:1071–1076.
 56. Carney R, Freedland K, Miller G, Jaffe AS: **Depression as a risk factor for cardiac mortality and morbidity: A review of potential mechanisms.** *J Psychosom Res* 2002, **53**:897–902.
- This is a comprehensive review of the mechanisms explaining the relationship between depression and mortality, with a focus on biological mechanisms.
57. Holsboer F: **The corticosteroid receptor hypothesis of depression.** *Neuropsychopharmacology* 2000, **23**:477–501.
 58. Pariante CM: **Depression, stress and the adrenal axis.** *J Neuroendocrinol* 2003, **15**:811–812.
 59. Musselman DL, Nemeroff CB: **Depression and endocrine disorders: focus on the thyroid and adrenal system.** *Br J Psychiatry Suppl* 1996, **30**:123–128.
 60. Bjorntorp P, Rosmond R: **Visceral obesity and diabetes.** *Drugs* 1999, **58**(suppl 1):13–18.
 61. Kaplan NM: **The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension.** *Arch Intern Med* 1989, **149**:1514–1520.
 62. Michelson D, Stratakis C, Hill L, et al.: **Bone mineral density in women with depression.** *N Engl J Med* 1996, **335**:1176–1181.
 63. Muller M, Holsboer F, Keck ME: **Genetic modification of corticosteroid receptor signalling: novel insights into pathophysiology and treatment strategies of human affective disorders.** *Neuropeptides* 2002, **36**:117–131.
 64. Krieg JC, Lauer CJ, Schreiber W, et al.: **Neuroendocrine, polysomnographic and psychometric observations in healthy subjects at high familial risk for affective disorders: the current state of the 'Munich vulnerability study'.** *J Affect Disord* 2001, **62**:33–37.
 65. Maes M, Meltzer HY, Bosmans E, et al.: **Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression.** *J Affect Disord* 1995, **34**:301–309.
 66. Penninx BW, Kritchinsky SB, Yaffe K, et al.: **Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study.** *Biol Psychiatry* 2003, **54**:566–572.
 67. Sapsolsky R, Rivier C, Yamamoto G, et al.: **Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor.** *Science* 1987, **238**:522–524.
 68. Ridker PM, Buring JE, Shih J, et al.: **Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.** *Circulation* 1998, **98**:731–733.
 69. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: **Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.** *Circulation* 2000, **101**:1767–1772.
 70. Shah PK: **Circulating markers of inflammation for vascular risk prediction: are they ready for prime time.** *Circulation* 2000, **101**:1758–1759.
 71. Cesari M, Penninx BW, Newman A, et al.: **Inflammatory markers and onset of cardiovascular events: results from the Health ABC study.** *Circulation* 2003, **108**:2317–2322.
 72. Reichenberg A, Yirmiya R, Schuld A, et al.: **Cytokine-associated emotional and cognitive disturbances in humans.** *Arch Gen Psychiatry* 2001, **58**:445–452.
 73. Roy A, Pickar D, De Jong J, et al.: **Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Relationship to hypothalamic-pituitary-adrenal axis function in depression.** *Arch Gen Psychiatry* 1988, **45**:849–857.
 74. Carney RM, Saunders RD, Freedland KE, et al.: **Association of depression with reduced heart rate variability in coronary artery disease.** *Am J Cardiol* 1995, **76**:562–564.
 75. Musselman DL, Evans DL, Nemeroff CB: **The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment.** *Arch Gen Psychiatry* 1998, **55**:580–592.
- Comprehensive, well written and illustrated review of biological mechanisms linking depression and cardiovascular disorders.
76. Alexopoulos GS, Buckwalter K, Olin J, et al.: **Comorbidity of late life depression: an opportunity for research on mechanisms and treatment.** *Biol Psychiatry* 2002, **52**:543–558.
 77. Thomas AJ, Kalaria RN, O'Brien JT: **Depression and vascular disease: what is the relationship?** *J Affect Disord* 2004, **79**:81–95.
 78. Catz SL, Kelly JA, Bogart LM, et al.: **Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease.** *Health Psychol* 2000, **19**:124–133.
 79. Richardson JL, Marks G, Johnson CA, et al.: **Path model of multidimensional compliance with cancer therapy.** *Health Psychol* 1987, **6**:183–207.
 80. Carney R: **Major depression and medication adherence in elderly patients with coronary artery disease.** *Health Psychology* 1995, **14**:88–90.
 81. DiMatteo MR, Lepper HS, Croghan TW: **Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence.** *Arch Intern Med* 2000, **160**:2101–2107.
 82. Wing RR, Phelan S, Tate D: **The role of adherence in mediating the relationship between depression and health outcomes.** *J Psychosom Res* 2002, **53**:877–881.
 83. Althaus D, Hegerl U: **The evaluation of suicide prevention activities: state of the art.** *World J Biol Psychiatry* 2003, **4**:156–165.
 84. Tondo L, Hennen J, Baldessarini RJ: **Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis.** *Acta Psychiatr Scand* 2001, **104**:163–172.
 85. Aseltine RH Jr, DeMartino R: **An outcome evaluation of the SOS Suicide Prevention Program.** *Am J Public Health* 2004, **94**:446–451.
 86. Motto JA, Bostrom AG: **A randomized controlled trial of post-crisis suicide prevention.** *Psychiatr Serv* 2001, **52**:828–833.
 87. Bruce M, Ten Have T, Katz I, et al.: **Reducing suicidal ideation and depressive symptoms in depressed older primary care patients. A randomized controlled trial.** *JAMA* 2004, **291**:1081–1091.
 88. Hall SM, Reus VI, Munoz RF, et al.: **Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking.** *Arch Gen Psychiatry* 1998, **55**:683–690.
 89. Hall SM, Munoz RF, Reus VI, et al.: **Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study.** *J Consult Clin Psychol* 1996, **64**:1003–1009.
 90. Hall SM, Munoz RF, Reus VI: **Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers.** *J Consult Clin Psychol* 1994, **62**:141–146.
 91. Patten CA, Martin JE, Myers MG, et al.: **Effectiveness of cognitive-behavioral therapy for smokers with histories of alcohol dependence and depression.** *J Stud Alcohol* 1998, **59**:327–335.
 92. Peterson AM, Takiya L, Finley R: **Meta-analysis of trials of interventions to improve medication adherence.** *Am J Health Syst Pharm* 2003, **60**:657–665.
 93. Glassman AH, Roose SP, Bigger JT: **The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered.** *JAMA* 1993, **269**:2673–2675.
 94. Roose SP, Glassman AH: **Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies.** *J Clin Psychiatry* 1994, **55**(suppl A):83–87.
 95. Avery D, Winokur G: **Mortality in depressed patients treated with electroconvulsive therapy and antidepressants.** *Arch Gen Psychiatry* 1976, **33**:1029–1037.
 96. Craig TJ, Lin SP: **Mortality among psychiatric inpatients. Age-adjusted comparison of populations before and after psychotropic drug era.** *Arch Gen Psychiatry* 1981, **38**:935–938.
 97. Sauer WH, Berlin JA, Kimmel SE: **Selective serotonin reuptake inhibitors and myocardial infarction.** *Circulation* 2001, **104**:1894–1898.
 98. Jorge RE, Robinson RG, Arndt S, Starkstein S: **Mortality and poststroke depression: a placebo-controlled trial of antidepressants.** *Am J Psychiatry* 2003, **160**:1823–1829.

99. Musselman DL, Marzec UM, Manatunga A, *et al.*: **Platelet reactivity in depressed patients treated with paroxetine: Preliminary findings.** *Arch Gen Psychiatry* 2000, **57**:875–882.
100. Budziszewska B, Jaworska-Feil L, Tetich M, *et al.*: **Regulation of the human corticotropin-releasing-hormone gene promoter activity by antidepressant drugs in Neuro-2A and AtT-20 cells.** *Neuropsychopharmacology* 2004, **29**:785–794.
101. Nemeroff CB, Owens MJ: **Pharmacologic differences among the SSRIs: Focus on monoamine transporters and the HPA axis.** *CNS Spectr* 2004, **9**(suppl 4):23–31.
102. Glassman AH, O'Connor CM, Califf RM, *et al.*: **Sertraline treatment of major depression in patients with acute MI or unstable angina.** *JAMA* 2002, **288**:701–709.
103. Berkman LF, Blumenthal J, Burg M, *et al.*: **Enhancing Recovery in Coronary Heart Disease Patients Investigators (ENRICHD). Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial.** *JAMA* 2003, **289**:3106–3116.
104. Linden W, Stossel C, Maurice J: **Psychosocial interventions for patients with coronary artery disease: a meta-analysis.** *Arch Intern Med* 1996, **156**:745–752.